摘要
过去的十年,是免疫治疗进入临床实践取得巨大发展的十年。单一靶点治疗不能满足患者的需求,因此出现一些双特异性抗体或多靶点联合治疗的药物。Bintrafusp alfa(M7824)是一种双功能融合蛋白,由抗程序性死亡配体-1(PD-L1)融合到人类转化生长因子-β(TGF-β)受体Ⅱ的胞外域组成。通过两端的靶点,M7824能有效、特异地与PD-L1和TGF-β相结合,最终增强CD8^(+)T细胞和NK细胞的抗肿瘤活性。本文对M7824的作用机制、临床研究及发展前景进行综述。
In the past ten years,immunotherapy has made great progress in clinical practice.Single-target therapy can-not meet the needs of patients,so there are some bispecific antibodies or multi-target combination therapy drugs.Bintra-fusp alfa(M7824)is a kind of bifunctional fusion protein,which consists of the extracellular domain of anti-programmed death ligand-1(PD-L1)fused to human transforming growth factor-β(TGF-β)receptor II.Through targeting at both ends,M7824 can effectively and specifically bind to PD-L1 and TGF-β,ultimately increasing the anti-tumor activity of CD8^(+)T cells and NK cells.This article reviews the action mechanism,clinical studies and development prospects of M7824.
作者
周俊邑
仲小敏
ZHOU Junyi;ZHONG Xiaomin(The Huai’an Clinical College of Xuzhou Medical University,Huai’an,223300,Jiangsu,China)
出处
《肿瘤药学》
CAS
2023年第2期142-149,共8页
Anti-Tumor Pharmacy
基金
江苏省自然科学基金青年基金项目(BK20180271)。
